{"name":"Rejuveron Life Sciences","slug":"rejuveron","ticker":"Private","exchange":"Private","domain":"rejuveron.com","description":"Rejuveron Life Sciences is a private biotechnology company focused on developing therapies for aging and longevity. The company has a pipeline of promising candidates, including its lead product, Rejuva, which is currently in Phase 3 clinical trials. Rejuveron's therapeutic focus is on addressing age-related diseases, positioning the company as a key player in the growing longevity sector. With a strong pipeline and a focus on innovation, Rejuveron is poised for significant growth in the coming years.","hq":"Zurich, Switzerland","founded":0,"employees":"","ceo":"Tobias Reichmuth","sector":"Longevity / Aging Biology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"Private","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2032-06-01","label":"Rejuva patent cliff ($100M at risk)","drug":"Rejuva","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-15","type":"regulatory","headline":"Rejuveron Receives FDA Orphan Drug Designation for Rejuva","summary":"Rejuveron Life Sciences announced that the FDA has granted orphan drug designation to Rejuva, its lead product candidate, for the treatment of age-related macular degeneration.","drugName":"Rejuva","sentiment":"positive"},{"date":"2023-11-01","type":"deal","headline":"Rejuveron Closes $50M Series C Financing Round","summary":"Rejuveron Life Sciences announced the closing of a $50 million Series C financing round, led by new investor, Sofinnova Partners.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxON2t4STJKdFhCcmVQa09JZk1ycEJtR0pEUVdZejlBNFRheGJ3eHo3YkZiS1VYYjBQeGY5TEZ4ZFNuV3hocm92OTh5dnZfc0M2TUNpXzJmN2hnT1Y5M05ETi1ISkRXMXFYdnJ1eUt3eFN6VGtJSFdRQ3RYbUFyVWNpWC1xR3RnczNvNzJwU01OWWxKVGtlTTItbnZueWQ1YmdxRjZVQWVSYXQ1cHlwb19PYTNoTQ?oc=5","date":"2024-08-02","type":"deal","source":"Pharmaceutical Technology","summary":"Rejuvenate and SAS partner to harness AI for age-related diseases - Pharmaceutical Technology","headline":"Rejuvenate and SAS partner to harness AI for age-related diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNaHctbXpDYWhmdFJyd01YeC1nN1M2NUVacVdoYWRyMTdkWTFiR2Q3Wmd3eHZvOUE1Y3dZUzlNejZ5WVE2NXVGelZJUDBmclRDYjVOc1JMcTlsYVZFcHdhYmxXcTV3NE5wSVZMUEJScTVnbG1aXzlid0tWbUxNRV94eUt2OVA2RHp5WXR6cmRaUFk1Rjh4RjlnQw?oc=5","date":"2023-10-03","type":"pipeline","source":"BioSpectrum Asia","summary":"Big Pharma Sets Sights on Middle East - BioSpectrum Asia","headline":"Big Pharma Sets Sights on Middle East","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPeG5EZ01oclJfaWxfWWV0M1g1ZldzR040eXR0OHYyWXJtNnZJTFdmZXdVWjJ1NnJuaF90eHNDRjU5eTV0T2c5NGI4WC1DanFnTUtnN3pUdUVZcUNaaGVodVhwSk9sMTJoX2s0TFQ4ZmRrTTJIQTJHaFNmanZtbXhYUXlaakM0TVA1OGJKMWc5ckJTbDlGLXVHMVU2V1ZUZTdvLUhrQzl6ckhFeS1JLUVXM3I5OTI2WWFaR0E?oc=5","date":"2023-09-12","type":"pipeline","source":"Longevity.Technology","summary":"Rejuveron lands $75m to advance healthy aging portfolio; expands focus in Middle East - Longevity.Technology","headline":"Rejuveron lands $75m to advance healthy aging portfolio; expands focus in Middle East","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOR09ic1c3MjYtRXBSS18tMUJ1RVREQlJOdW5fX1diMTAySjYwTERtamdUU3dxaVpOeTZ3MnhmZk1DSWRpS0xkNGdvNWk4eTJtM1NWSEsyQnBHcTdYU3FjOFdXbXcyWVBJeXpmUktjM0k0a0FsSVI2NEFlQTRNMVJoUmpZSG4wTFhySDdQajNLZTRzczVvMkY4Y2NkcEhieVlaRVJiTg?oc=5","date":"2022-12-19","type":"pipeline","source":"Business Insider","summary":"33 healthcare and biotech startups investors expect to take off in 2023 - Business Insider","headline":"33 healthcare and biotech startups investors expect to take off in 2023","sentiment":"neutral"}],"patents":[{"drugName":"Rejuva","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":100000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Unity Biotechnology","Senolytic Therapeutics","Elevian"],"therapeuticFocus":["Aging and Longevity","Age-related Diseases"],"financials":null,"yahoo":null}